Jacob J Mandel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/438635/publications.pdf

Version: 2024-02-01

44 papers 843 citations

687363 13 h-index 28 g-index

44 all docs

44 docs citations

44 times ranked 1570 citing authors

#	Article	IF	CITATIONS
1	Practical guidance for telemedicine use in neuro-oncology. Neuro-Oncology Practice, 2022, 9, 91-104.	1.6	1
2	Racial and Socioeconomic Disparities in Patients With Meningioma: A Retrospective Cohort Study. Neurosurgery, 2022, 90, 114-123.	1.1	8
3	Hemorrhagic cavum vergae colloid cyst: A presentation of anterograde amnesia without hydrocephalus. , 2022, 13, 148.		1
4	Could patients benefit from whole-brain radiotherapy with unilateral hippocampus sparing?. Reports of Practical Oncology and Radiotherapy, 2021, 26, 454-456.	0.6	2
5	Multicentric non-enhancing lesions in glioblastoma: A retrospective study. Journal of Clinical Neuroscience, 2021, 85, 20-26.	1.5	1
6	The concurrence of multiple sclerosis and glioblastoma. Multiple Sclerosis and Related Disorders, 2021, 50, 102877.	2.0	5
7	Intracranial Solitary Fibrous Tumor of the Skull Base: 2 Cases and Systematic Review of the Literature. World Neurosurgery, 2021, 149, e345-e359.	1.3	6
8	IDH mutation status and the development of venous thromboembolism in astrocytoma patients. Journal of the Neurological Sciences, 2021, 427, 117538.	0.6	4
9	INNV-27. AN INNOVATIVE VIRTUAL MULTI-INSTITUTIONAL, MULTIDISCIPLINARY NEURO-ONCOLOGY TUMOR BOARD: THE NIH-NOB EXPERIENCE DURING THE COVID-19 PANDEMIC. Neuro-Oncology, 2021, 23, vi111-vi111.	1.2	O
10	Decreasing incidence of upper age restriction enrollment criteria among cancer clinical trials. Journal of Geriatric Oncology, 2020, 11, 451-454.	1.0	28
11	Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro-Oncology, 2020, 22, 539-549.	1.2	98
12	Exclusion of patients with brain metastases from cancer clinical trials. Neuro-Oncology, 2020, 22, 577-579.	1.2	18
13	Paraneoplastic syndromes in small cell lung cancer. Journal of Thoracic Disease, 2020, 12, 6253-6263.	1.4	34
14	Pineal parenchymal tumor of intermediate differentiation: a single-institution experience. Neuro-Oncology Practice, 2020, 7, 613-619.	1.6	7
15	Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLC. Journal of Oncology, 2020, 2020, 1-8.	1.3	3
16	Hyperostosis frontalis interna diagnosed after a provoked seizure. BMJ Case Reports, 2020, 13, e236520.	0.5	5
17	Spinal meningioma in a patient with multiple sclerosis. , 2020, 11, 196.		0
18	BIOM-01. TYROSINE KINASE INHIBITORS AS A TREATMENT OF SYMPTOMATIC CNS METASTASES IN ONCOGENE-DRIVEN NSCLC. Neuro-Oncology, 2020, 22, ii1-ii1.	1.2	0

#	Article	IF	Citations
19	NCMP-10. IDH MUTATION STATUS AND THE DEVELOPMENT OF VENOUS THROMBOEMBOLISM IN ASTROCYTOMA PATIENTS. Neuro-Oncology, 2020, 22, ii125-ii125.	1.2	O
20	Treatment strategies for glioblastoma in older patients: age is just a number. Journal of Neuro-Oncology, 2019, 145, 357-364.	2.9	12
21	Effect of health disparities on overall survival of patients with glioblastoma. Journal of Neuro-Oncology, 2019, 142, 365-374.	2.9	9
22	Factors Associated With Age Disparities Among Cancer Clinical Trial Participants. JAMA Oncology, 2019, 5, 1769.	7.1	161
23	Recurrent Papillary Glioneuronal Tumor. World Neurosurgery, 2019, 128, 127-130.	1.3	7
24	Newly Diagnosed Optic Pathway Glioma During Pregnancy. World Neurosurgery, 2019, 127, 58-62.	1.3	2
25	QOLP-30. CLINICAL PREDICTIVE MODEL FOR THE DEVELOPMENT OF VENOUS THROMBOEMBOLISM IN GLIOBLASTOMA. Neuro-Oncology, 2019, 21, vi204-vi204.	1.2	1
26	HOUT-18. TREATMENT STRATEGIES FOR GLIOBLASTOMA IN OLDER PATIENTS: AGE IS JUST A NUMBER. Neuro-Oncology, 2019, 21, vi115-vi116.	1.2	1
27	Gastrointestinal stromal tumor with intracranial metastasis: case presentation and systematic review of literature. BMC Cancer, 2019, 19, 1119.	2.6	13
28	Disparities along the glioblastoma clinical trials landscape. Neuro-Oncology, 2019, 21, 285-286.	1.2	6
29	Spinal Dural Arteriovenous Fistula and Concomitant Intramedullary Spinal Lesion. Canadian Journal of Neurological Sciences, 2018, 45, 238-239.	0.5	0
30	Neurologic complications of immune checkpoint inhibitors. Journal of Neuro-Oncology, 2018, 137, 601-609.	2.9	126
31	Intracranial Erdheim-Chester Disease Mimicking Parafalcine Meningioma: Report of Two Cases and Review of the Literature. World Neurosurgery, 2018, 110, 365-370.	1.3	5
32	Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma. Neuro-Oncology, 2018, 20, 113-122.	1.2	56
33	ATIM-07. WINDOW-OF-OPPORTUNITY CLINICAL TRIAL OF PEMBROLIZUMAB IN RECURRENT GLIOBLASTOMA PATIENTS. Neuro-Oncology, 2018, 20, vi2-vi2.	1.2	0
34	EPID-08. EFFECT OF HEALTH DISPARITIES ON OVERALL SURVIVAL OF PATIENTS WITH GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi81-vi81.	1.2	0
35	Highlighting the need for reliable clinical trials in glioblastoma. Expert Review of Anticancer Therapy, 2018, 18, 1031-1040.	2.4	12
36	Radiographic patterns of progression with associated outcomes after bevacizumab therapy in glioblastoma patients. Journal of Neuro-Oncology, 2017, 135, 75-81.	2.9	14

#	Article	IF	CITATIONS
37	Intraventricular Cavernomas of the Third Ventricle: Report of 2 Cases and a Systematic Review of the Literature. World Neurosurgery, 2017, 105, 935-943.e3.	1.3	24
38	Newly diagnosed ganglioglioma in an adult patient with multiple sclerosis. Journal of the Neurological Sciences, 2016, 369, 51-52.	0.6	4
39	Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma. Journal of Neuro-Oncology, 2016, 129, 147-154.	2.9	36
40	Intracranial epithelioid hemangioendothelioma causing subacute loss of vision. Neurology, 2015, 85, 735-736.	1.1	3
41	Delayed imaging abnormalities of neuro-invasive West Nile virus in cancer patients. Journal of the Neurological Sciences, 2015, 350, 115-117.	0.6	3
42	Primary and secondary gliosarcomas: clinical, molecular and survival characteristics. Journal of Neuro-Oncology, 2015, 125, 401-410.	2.9	59
43	Wound healing complications in brain tumor patients on Bevacizumab. Journal of Neuro-Oncology, 2015, 124, 501-506.	2.9	18
44	Leptomeningeal dissemination in glioblastoma; an inspection of risk factors, treatment, and outcomes at a single institution. Journal of Neuro-Oncology, 2014, 120, 597-605.	2.9	50